ArcScan, Inc. Signs Definitive Agreement for $11.15 Million Preferred Series B Investment with Shanghai Haohai Biological Technology Ltd.
Jul 21, 2021
GOLDEN, Colo., July 21, 2021 /PRNewswire/ -- ArcScan, Inc., the developer of state-of-the-art ophthalmic ultrasound imaging device "ArcScan Insight® 100, " headquartered in Golden, Colorado, announces the execution of a Stock Purchase Agreement with Shanghai Haohai Biological Technology Ltd. ("Haohai") that will result in a $11.15 million Preferred Series B investment into ArcScan, Inc. Haohai is a leading Chinese ophthalmology and medical aesthetics company headquar